2023 年 10 月，在德国接受治疗的一名乌克兰患者的 XDR 临床分离株中首次检测到 RpoB I491F 突变。
First detection of a XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023.
机构信息
Research Center Borstel, Leibniz Lung Center, Supranational and National Reference Center for Mycobacteria, Borstel, Germany.
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
出版信息
Euro Surveill. 2024 Jul;29(28). doi: 10.2807/1560-7917.ES.2024.29.28.2400420.
Abstract
This report documents the case of a Ukrainian patient infected with an extensively drug-resistant (XDR) lineage 2 strain harbouring the rifampicin resistance mutation RpoB I491F. This mutation is not detected by routine molecular WHO-recommended rapid diagnostics, complicating the detection and treatment of these strains. The occurrence of such mutations underscores the need for enhanced diagnostic techniques and tailored treatment regimens, especially in eastern Europe where lineage 2 strains and XDR-tuberculosis are prevalent.
摘要
本报告记录了一例乌克兰患者感染利福平耐药突变 RpoB I491F 的广泛耐药（XDR）株 2 型菌株的情况。这种突变不能被常规的分子 WHO 推荐的快速诊断检测到，这增加了这些菌株的检测和治疗的复杂性。这种突变的出现突显了需要增强诊断技术和制定个体化的治疗方案，特别是在东欧，那里 2 型菌株和广泛耐药结核病流行。
相似文献
1
First detection of a XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023.2023 年 10 月，在德国接受治疗的一名乌克兰患者的 XDR 临床分离株中首次检测到 RpoB I491F 突变。
Euro Surveill. 2024 Jul;29(28). doi: 10.2807/1560-7917.ES.2024.29.28.2400420.
2
Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.对印度结核患者临床分离株进行全基因组测序：真实世界数据显示存在较高比例的预广泛耐药病例。
Microbiol Spectr. 2024 May 2;12(5):e0277023. doi: 10.1128/spectrum.02770-23. Epub 2024 Apr 10.
3
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.四十年间广泛耐药结核病的演变：来自夸祖鲁 - 纳塔尔省结核分枝杆菌分离株的全基因组测序与年代分析
PLoS Med. 2015 Sep 29;12(9):e1001880. doi: 10.1371/journal.pmed.1001880. eCollection 2015 Sep.
4
Next-Generation Sequencing for Characterizing Drug Resistance-Conferring Mycobacterium tuberculosis Genes from Clinical Isolates in the Ukraine.从乌克兰临床分离株中鉴定耐药相关结核分枝杆菌基因的下一代测序。
J Clin Microbiol. 2018 May 25;56(6). doi: 10.1128/JCM.00009-18. Print 2018 Jun.
5
Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.通过直接测序从痰涂片阳性样本中早期检测耐多药和广泛耐药前结核病
BMC Infect Dis. 2017 Apr 24;17(1):300. doi: 10.1186/s12879-017-2409-6.
6
Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.耐多药结核分枝杆菌在结核病转诊中心的尼泊尔患者中。
PLoS One. 2024 May 6;19(5):e0301210. doi: 10.1371/journal.pone.0301210. eCollection 2024.
7
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.在一个耐药结核病发病率较低的国家，表型上对利福平敏感的结核分枝杆菌分离株中出现有争议的 rpoB 突变。
BMC Infect Dis. 2019 Jan 3;19(1):3. doi: 10.1186/s12879-018-3638-z.
8
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated from south-central in China.中国中南部地区耐多药结核分枝杆菌的分子特征。
J Antibiot (Tokyo). 2014 Apr;67(4):291-7. doi: 10.1038/ja.2013.133. Epub 2013 Dec 11.
9
Whole genome sequencing of clinical samples reveals extensively drug resistant tuberculosis (XDR TB) strains from the Beijing lineage in Nigeria, West Africa.对临床样本进行全基因组测序揭示了来自西非尼日利亚的北京谱系的广泛耐药结核病（XDR-TB）菌株。
Sci Rep. 2021 Aug 30;11(1):17387. doi: 10.1038/s41598-021-96956-7.
10
Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan.巴基斯坦广泛耐药结核分枝杆菌分离株耐药突变特征。
Antimicrob Agents Chemother. 2011 Dec;55(12):5654-9. doi: 10.1128/AAC.05101-11. Epub 2011 Sep 12.
引用本文的文献
1
Single-Sample Melt-Based Screening for Rifampicin Susceptibility in the Emerging Mutation Hotspot at Codon 491.基于单样本熔解曲线分析的利福平敏感性检测在密码子491新兴突变热点中的应用
ACS Infect Dis. 2025 Jul 11;11(7):1934-1943. doi: 10.1021/acsinfecdis.5c00150. Epub 2025 Jun 17.
2
Letter to the Editor: First detection of a XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023.致编辑的信：2023年10月，在德国接受治疗的一名乌克兰患者中首次检测到携带RpoB I491F突变的广泛耐药临床分离株。
Euro Surveill. 2024 Oct;29(42). doi: 10.2807/1560-7917.ES.2024.29.42.2400665.
本文引用的文献
1
Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study.莫桑比克出现对贝达喹啉耐药的结核病以及携带rpoB基因Ile491Phe突变的耐多药和广泛耐药结核分枝杆菌菌株，而Xpert MTB/RIF未检测到该突变：一项回顾性观察研究。
Lancet Infect Dis. 2024 Mar;24(3):297-307. doi: 10.1016/S1473-3099(23)00498-X. Epub 2023 Nov 10.
2
Tuberculosis Variant with Rifampin Resistance Undetectable by Xpert MTB/RIF, Botswana.对利福平耐药的结核分枝杆菌变异体的检测，博茨瓦纳，Xpert MTB/RIF 法无法检出。
Emerg Infect Dis. 2023 Nov;29(11):2403-2406. doi: 10.3201/eid2911.230987.
3
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis.结核分枝杆菌中贝达喹啉和氯法齐明耐药性：体外和计算机模拟数据分析。
Lancet Microbe. 2023 May;4(5):e358-e368. doi: 10.1016/S2666-5247(23)00002-2. Epub 2023 Mar 29.
4
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.评估用于治疗结核病的普瑞马尼德（APT），一项针对药物敏感型结核病的含普瑞马尼德治疗方案的随机2期试验：12周结果。
Am J Respir Crit Care Med. 2023 Apr 1;207(7):929-935. doi: 10.1164/rccm.202208-1475OC.
5
First Detection of Mycobacterium tuberculosis Clinical Isolates Harboring I491F Borderline Resistance Mutation in Myanmar.在缅甸首次检测到携带I491F临界耐药突变的结核分枝杆菌临床分离株。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0092522. doi: 10.1128/aac.00925-22. Epub 2022 Nov 7.
6
On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.结核菌复合群利福平药敏试验中界定不当的断点的后果
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.02328-20.
7
MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.斯威士兰 Xpert 漏检的耐多药结核分枝杆菌暴发克隆株具有较高的贝达喹啉耐药性，可追溯到治疗前时代。
Genome Med. 2020 Nov 25;12(1):104. doi: 10.1186/s13073-020-00793-8.
8
Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis.利福平存在时pretomanid的药代动力学：结核病患者随机试验的中期结果
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01196-20.
9
Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study.南非耐多药结核病爆发未被世界卫生组织认可的商业检测方法检出：一项观察性研究。
Lancet Infect Dis. 2018 Dec;18(12):1350-1359. doi: 10.1016/S1473-3099(18)30496-1. Epub 2018 Oct 18.
10
Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland.在斯威士兰通过Xpert MTB/RIF检测耐多药结核病
N Engl J Med. 2015 Mar 19;372(12):1181-2. doi: 10.1056/NEJMc1413930.
Zotero 插件